Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LN-145 in Metastatic Triple Negative Breast Cancer
NCT04111510Phase 2Completed
- Sponsor
- Yale University
- Start
- Dec 2019
- Primary completion
- Jan 2023
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LN-145 in triple negative breast cancer (TNBC), sponsored by Yale University. Primary endpoints: Objective Response Rate at 4 months and Incidence of Grade >= 3 TEAEs at 3 years. Started Dec 2019; status: completed.
02
Drugs
LN-145
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04111510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111510.